CompletedNCT03424824
BP1.3656 for Alcohol Use: A Placebo-Controlled Study
About this title
Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment
Read the official source — NCT03424824Researchers compared BP1.3656 low dose, BP1.3656 intermediate dose, BP1.3656 high dose and placebo to find out how the approaches affected alcohol use in people with alcohol dependence.
Medication studyAges 18–65Multiple countriesAddiction
Understand this study
What did researchers investigate?
Researchers compared BP1.3656 low dose, BP1.3656 intermediate dose, BP1.3656 high dose and placebo to find out how the approaches affected alcohol use in people with alcohol dependence.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Sofia and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: January 9, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 210
- Sponsor
- Bioprojet
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, Bulgaria, Russia
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03424824
- Official title
Show the full official title
A Multisite Randomized Clinical Trial Evaluating BP1.3656 Vs Placebo For Alcohol Use Disorder Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedSofia, Bulgaria · Amiens, France · Saint Petersburg, Russia
1 more locations
- Russia
Questions about this study
What did researchers investigate?
Researchers compared BP1.3656 low dose, BP1.3656 intermediate dose, BP1.3656 high dose and placebo to find out how the approaches affected alcohol use in people with alcohol dependence.
Who is behind this study?
The study sponsor is Bioprojet.
Did this study involve medication?
Yes. The study involved medication, including BP1.3656 low dose, BP1.3656 intermediate dose, Placebo and BP1.3656 high dose.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults with A...
A Multisite Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Addiction Treatment